Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 39Neoplasms 37Depression 29Prostatic Neoplasms 23Fatigue 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 13Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Pain 11Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 11Lymphoma, Large-Cell, Immunoblastic 10Leukemia, Myeloid, Acute 10Colorectal Neoplasms 10Leukemia, Myeloid, Chronic-Phase 9Hodgkin Disease 9Blast Crisis 9Vomiting 8Nausea 8Lymphoma 8Leukemia, Myeloid, Accelerated Phase 8Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 16Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Glioma × Therapeutics × Clear all
NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

Massachusetts General Hospital

Phase EARLY_PHASE1 Active not recruiting
16 enrolled
CNS

Glioma

NCT06305910 2024-03-12

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

OX2 Therapeutics

Phase 1 Recruiting
24 enrolled
CNS

Glioma

NCT00360828 2017-03-23

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
10 enrolled 6 charts
CNS

Astrocytoma, Brain Neoplasms, Glioma, Neurologic Manifestations, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡